Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/16/2025

Treatment of Benign Prostatic Hyperplasia

Primary Treatment Options

  • Alpha-blockers are first-line medical therapy for BPH, working by inhibiting alpha1-adrenergic-mediated contraction of prostatic smooth muscle to relieve bladder outlet obstruction, as recommended by the American Urological Association 1
  • 5-alpha-reductase inhibitors are appropriate for patients with lower urinary tract symptoms (LUTS) associated with demonstrable prostatic enlargement, according to the European Association of Urology 2
  • 5-alpha-reductase inhibitors are not appropriate treatments for men with LUTS who do not have evidence of prostatic enlargement, as stated by the American Urological Association 2
  • Surgical intervention remains appropriate for patients with moderate-to-severe LUTS who have failed medical therapy or developed complications of BPH, as recommended by the European Association of Urology 3

Role of Antimuscarinics in BPH Management

  • Antimuscarinics like oxybutynin are primarily indicated for overactive bladder symptoms, not for BPH itself, according to the European Urology guidelines 4
  • Oxybutynin and other antimuscarinics may be used as add-on therapy to alpha-blockers in men with residual storage symptoms (urgency, frequency) despite alpha-blocker treatment, as suggested by the European Urology guidelines 4
  • The combination of an alpha-blocker plus an antimuscarinic may be more effective than monotherapy for men with BPH who have both storage and voiding symptoms, as recommended by the European Urology guidelines 4
  • Assessing post-void residual volume before initiating antimuscarinic therapy is recommended, according to the European Urology guidelines 4